The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Of the most senior full time jobs on the career ladder to chief executive, such as divisional or regional heads, only 21% are ...

GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers: London, UK Thursday, November 14, 2024, 15:00 Hrs [IST] GSK plc announced t ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

I’m talking Tesco, Unilever or GSK, businesses that people use every day and are likely to continue doing so. Take Aviva (LSE: AV.), for example. As the largest general insurer in the UK, it’s ...

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...